Question 1

What is Boston Scientific's P/E ratio?

Accepted Answer

Boston Scientific (BSX) P/E ratio is 18.1× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Boston Scientific?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Boston Scientific specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is Boston Scientific's P/E ratio high or low?

Accepted Answer

Boston Scientific's P/E ratio of 18.1× is below its own 5-year average of 67.6× and below the sector median of 24.2×. That places the current reading at the 0th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Boston Scientific's historical P/E ratio range?

Accepted Answer

In the available daily series, Boston Scientific (BSX) P/E ratio has ranged from a low of 10.6× in 2020 to a high of 399.8× in 2016. The 5-year average is 67.6× and the 5-year median is 63.2×.

Question 7

What was Boston Scientific's P/E ratio in 2025?

Accepted Answer

Boston Scientific (BSX) P/E ratio at the end of 2025 was 48.9×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does Boston Scientific's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$141B	$2.89B	48.9×	-22.1×	Dec 31, 2025
2024	$132B	$1.85B	71.1×	+17.9×	Dec 31, 2024
2023	$84.7B	$1.59B	53.2×	-41.6×	Dec 31, 2023
2022	$66.3B	$699M	94.8×	+36.6×	Dec 31, 2022
2021	$60.5B	$1.04B	58.2×	—	Dec 31, 2021
2020	$51.3B	-$139M	—	—	Dec 31, 2020
2019	$63.1B	$4.7B	13.4×	-15.9×	Dec 31, 2019
2018	$48.9B	$1.67B	29.3×	-298.1×	Dec 31, 2018
2017	$34B	$104M	327.3×	+242.5×	Dec 31, 2017
2016	$29.5B	$347M	84.9×	—	Dec 31, 2016
2015	$23.9B	-$239M	—	—	Dec 31, 2015
2014	$17.6B	$267M	65.8×	—	Dec 31, 2014
2013	$16B	-$121M	—	—	Dec 31, 2013
2012	$7.83B	-$3.96B	—	—	Dec 31, 2012
2011	$7.72B	$415M	18.6×	—	Dec 31, 2011
2010	$11.6B	-$1.07B	—	—	Dec 31, 2010
2009	$13.6B	-$731M	—	—	Dec 31, 2009
2008	$11.6B	-$2.04B	—	—	Dec 31, 2008
2007	$17.4B	-$495M	—	—	Dec 31, 2007
2006	$25.3B	-$3.58B	—	—	Dec 31, 2006
2005	$20.3B	$628M	32.4×	+4.5×	Dec 31, 2005
2004	$29.6B	$1.06B	27.9×	-37.8×	Dec 31, 2004
2003	$31B	$472M	65.7×	+19.6×	Dec 31, 2003
2002	$17.2B	$373M	46.1×	—	Dec 31, 2002


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Boston Scientific (BSX) 2002-2026

P/E Ratio daily chart for Boston Scientific (BSX)

Historical P/E Ratio for Boston Scientific (BSX) from 2002 to 2025

About P/E Ratio at Boston Scientific (BSX)

Boston Scientific P/E Ratio by Year

Boston Scientific P/E Ratio 2025: 48.9×

Boston Scientific P/E Ratio 2024: 71.1×

Boston Scientific P/E Ratio 2023: 53.2×

Boston Scientific P/E Ratio 2022: 94.8×

Boston Scientific P/E Ratio 2021: 58.2×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Boston Scientific (BSX) Key Financials